Results 131 to 140 of about 17,802 (177)

MicroRNA Expression Profiles as Biomarkers of Response to Disease-Modifying Therapies in Multiple Sclerosis: A Systematic Review. [PDF]

Int J Mol Sci
Dumitreasă MI, Maier S, Bărcuțean L, Manu D, Crauciuc GA, Buțiu O, Bălașa R.   +6 more
europepmc   +1 more source

The multifactorial nature of reproductive decision-making among women with multiple sclerosis. [PDF]

Eur J Midwifery
Dourou P, Gourounti K, Jotautis V, Lykeridou A, Theodorou S, Orologas A, Sousamli A, Petrogiannis N, Sarantaki A.   +8 more
europepmc   +1 more source

Visceral leishmaniasis in a multiple sclerosis patient: a rare complication of fingolimod-induced lymphopenia. [PDF]

Rev Esp Quimioter
García-Alabarce A, Cornejo-Calvo E, de Salazar-González A, Guirao-Arrabal E.   +3 more
europepmc   +1 more source

Triple-Frequency Electromagnetic Stimulation Combined with Fingolimod Reduces Breast Cancer Cell Proliferation and Metastasis-Associated Extracellular Vesicle Protein Levels. [PDF]

Pharmaceuticals (Basel)
Haroutunian G, Daniels L, Tsaghikian A, Zhao C, Zavras P, Marukian S, Zheng H, Mosoian A.   +7 more
europepmc   +1 more source

Repeatedly occurring retrograde menstruation intensifies central sensitization driven by neuroinflammation in endometriosis models. [PDF]

J Clin Invest
Harvey ME, Shi M, Oh Y, Page TM, Mitchell DA, Luo A, Slayden OD, MacLean JA, Sharma A, Hayashi K.   +9 more
europepmc   +1 more source

Systemic humoral activation facilitates tissue regeneration by D-chiral biomaterial scaffolds. [PDF]

Cell Biomater
Caston ELP, Lee Y, Alvarado PC, Espinoza AC, Segura T.   +4 more
europepmc   +1 more source

Real-world siponimod use in secondary progressive multiple sclerosis: the RESYZE study. [PDF]

Ther Adv Neurol Disord
Oreja-Guevara C, Gómez-Estévez I, Agüado García L, Martín Martínez J, Gómez Gutiérrez M, Gascón Giménez F, Agüera Morales E, Meca-Lallana V, Barrero Hernández FJ, González Quintanilla V, Romero Pinel L, Delgado Gil V, Durán Ferreras E, Blasco Quílez R, Meca-Lallana J, Landete Pascual L, Aladro-Benito Y, Boyero Durán S, Gracia Gil J, Caminero Rodríguez AB, Cano Orgaz AT, Eichau Madueño S, Querol Pascual MR, Otano Martínez M, Alonso Torres AM, Calles Hernández C, López Real A, Ares Luque A, Lorenzo González JR, Gómez Vicente L, Díaz Sánchez M.   +30 more
europepmc   +1 more source

Therapeutic Outcomes of Fingolimod and Interferon Beta-1a in Relapsing-Remitting Multiple Sclerosis: A Real-World Study from Jordan. [PDF]

Medicina (Kaunas)
Al Anber A, Abu Al Karsaneh O, Abuquteish D, Abdallah O, Issa MA, Sa'adeh M, Kilani D.   +6 more
europepmc   +1 more source

Pilot Study of Fingolimod Treatment in Neuronal Ceroid Lipofuscinosis Type 1. [PDF]

Neurol Genet
Messina M, Whiteley R, Gan C, Heywood WE, Heslegrave AJ, Keating M, Taylor S, Footitt E, Mills P, Hemingway C, Gissen P, Vecchiato K.   +11 more
europepmc   +1 more source

Fingolimod Effects on Motor Function and BDNF-TrkB Signaling in a Huntington's Mouse Model Are Disease-Stage-Dependent. [PDF]

Int J Mol Sci
Nguyen KQ, Rymar VV, Sadikot AF.
europepmc   +1 more source